Short-term efficacy of adalimumab in ulcerative colitis: A multicentre, prospective observational study

Our aim was to assess the clinical benefit and the tolerability of adalimumab, a fully human monoclonal antibody to tumor necrosis factor (TNF), in patients with ulcerative colitis (UC) at different Hungarian centers. Methods: Patients with active UC, including those who had lost response or developed intolerance to infliximab, were enrolled in a 52-week uncontrolled trial. Patients were treated with adalimumab of 160 or 80 mg at week 0, 80 or 40 mg at week 2, and 40 mg every other week. Outcome measures included the rate of clinical response and remission at week 12 and 52. Results: Forty-one patients were enro…